(CercleFinance.com) – UBS reaffirms its ‘buy’ recommendation on AstraZeneca with a price target maintained at 13,000 pence, representing a potential increase of 25% for the stock, welcoming the acquisition of Gracell by the British pharmaceutical laboratory.
According to the broker, this acquisition announced last week provides the group ‘with a cell therapy with promising preliminary data, as well as a platform which could shorten production times for cell therapies’.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
